BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 19213065)

  • 1. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MATCH results: implications for the internist.
    Lutsep HL
    Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
    Poredos P; Jezovnik MK
    Int Angiol; 2010 Feb; 29(1):20-6. PubMed ID: 20224527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
    Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
    J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    ; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
    N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
    Milani RV
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S7-S11. PubMed ID: 19213064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH; Bhatt DL; Fox KA; Steinhubl SR; Brennan DM; Hacke W; Mak KH; Pearson TA; Boden WE; Steg PG; Flather MD; Montalescot G; Topol EJ;
    Eur Heart J; 2007 Sep; 28(18):2200-7. PubMed ID: 17673448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
    Gorelick P; Sechenova O; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
    Hankey GJ
    Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.